Upcoming EL-PFDD Meetings
Similar Posts
Revance Therapeutics – 7/15/2022
Revance Therapeutics – 7/15/2022. Country: USA. Record Type: 483Early Alert: Anesthesia System Issue from GE HealthCare
GE HealthCare issues updated use instructions for certain Carestation 600 and 700 series Anesthesia SystemsMediNatura New Mexico, Inc. Issues Voluntary Nationwide Recall of ReBoost Nasal Spray Due to Microbial Contamination
FOR IMMEDIATE RELEASE – December 10, 2025 – Albuquerque, New Mexico, MediNatura New Mexico, Inc. is voluntarily recalling one lot of ReBoost Nasal Spray to the consumer level. The product has been found to contain yeast/mold and microbial contamination with one species identified as Achromobacter, aDaewoo Pharmaceutical Co., Ltd. – 706371 – 07/02/2025
CGMP/Finished Pharmaceuticals/AdulteratedCDER/Office of New Drugs Streamlined Nonclinical Studies and Acceptable New Approach Methodologies (NAMs)
It has become increasingly clear that new approach methodologies (NAMs)—when combined with knowledge of the pathway, results of pharmacology studies, and other relevant data—may offer ways to reduce animal testing.Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure
FDA’s surrogate endpoint table provides valuable information for drug developers on endpoints that may be considered and discussed with FDA for individual development programs.
